首页> 外国专利> Carbonyl-ethyl-carboxamidyl-alkane and carbonyl-ethyl-thiocarboxamidyl-alkane derivatives useful as antipicornaviral agents

Carbonyl-ethyl-carboxamidyl-alkane and carbonyl-ethyl-thiocarboxamidyl-alkane derivatives useful as antipicornaviral agents

机译:羰基-乙基-羧酰胺基-烷烃和羰基-乙基-硫代羧酰胺基-烷烃衍生物可用作抗玉米角病毒药物

摘要

A compound, a pharmaceutically acceptable prodrug, salt, active metabolite or solvate thereof has the formula (I) wherein: M is O or S; R1 is H, F, alkyl, OH, SH or O-alkyl; R2 and R5 are independently H, a group of formula 2a or formula 2b or alkyl provided that the alkyl is different from formula 2a or 2b further provided that at least one of R2 or R5 must be a group of formula 2a or 2b; R3 and R6 are independently H, F, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C(O)R17, -OR17, -SR17, -NR17R18, -NR19NR17R18 or -NR17OR18 or R3 and R6 together with the carbon atom to which they are attached form cycloalkyl or heterocycloalkyl; R7 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -OR17, -SR17, -NR17R18, -NR19NR17R18 or -NR17OR18 or R7 together with R3 or R6 and the atoms to which they are attached forms heterocycloalkyl; Z and Z1 are independently H, F, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -C(O)R21, -CO2R21, -CN, -C(O)NR21R22, -C(O)NR21OR22, -C(S)R21, -C(S)NR21R22, -NO2, -SOR21, -SO2R21, -SO2NR21R22, -SO(NR21)(OR22), -SONR21, -SO3R21, -PO(OR21)2, -PO(R21)(R22), -PO(NR21R22)(OR23), -PO(NR21R22)(NR23R24), -C(O)NR21NR22R23 or -C(S)NR21NR22R23 or Z1 together with R1 and the atoms to which Z1 and R1 are bonded form cycloalkyl or heterocycloalkyl or Z and Z1 together with the atoms to which they are bonded form cycloalkyl or heterocycloalkyl; in formula 2a: a) X is -CR2-, -CF2-, -CHF- or -S- and Y1 is -O-, -S-, -NR12-, -C(R13)(R14)-, -C(O)-, -C(S)- or -C(CR13R14)-; b) X is =CH or =CF and Y1 is =CH or =CF or c) X and Y1 together with Q' form a three- membered ring in which Q' is -C(R10)(R11)- or -O-, X is -CH- or -CF- and Y1 is -CH-, -CF- or -C(alkyl)-; A1 is C, CH, CF, S, P, Se, N, NR15, S(O), Se(O), P-OR15 or P-NR15R16; D1 is a moiety with a lone pair of electrons capable of forming a hydrogen bond; B1 is H, F, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -OR17, -SR17, -NR17R18, -NR19NR17R18 or -NR17OR18 or together D1 - A1 - B1 optionally forms a nitro group where A1 is N provided that i) when D1 is the moiety ºN with a lone pair of electrons capable of forming a hydrogen bond, B1 does not exist; and ii) when A1 is an sp3 carbon, B1 is not -NR17R18 when D1 is the moiety -NR25R26 with a lone pair of electrons capable of forming a hydrogen bond; In formula 2b: d) X is -CR2-, -CF2-, -CHF- or -S- and Y2 is -O-, -S-, -NR'12-, -C(R'13)(R'14)-, -C(O)-, -C(S)-, or -C(CR'13R'14)-; e) X is =CH or =CF and Y2 is =CH or =CF or f) X and Y2 together with Q' form a three- membered ring wherein Q' is -C(R10)(R11)- or -O-, X is -CH- or -CF- and Y2 is -CH-, -CF- or - C(alkyl); A2 is C, CH, CF, S, P, Se, N, NR15, S(O), Se(O), P-OR15 or P-NR15R16; D2 is a moiety with a lone pair of electrons capable of forming a hydrogen bond and B2 is H, F, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -OR17, -SR17, -NR17R18, -NR19NR17R18 or -NR17OR18 or any combination of Y2, A2, B2, and D2 optionally can form cycloalkyl, heterocycloalkyl, aryl or heteroaryl provided that when D2 is the moiety ºN with a lone pair of electrons capable of forming a hydrogen bond, B2 does not exist; R10 and R11 independently are H, halogen or alkyl or together with the carbon atom to which they are attached form cycloalkyl or heterocycloalkyl; R12 is H or alkyl; R'12 is H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -OR'13, -NR'13R'14, C(O)R'13, -SO2-R'13 or -C(S)R'13; R13 and R14 independently are H, F or alkyl or together with the atoms to which they are bonded form a cycloalkyl group or a heterocycloalkyl group; R'13 and R'14 independently are H, F or alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl or together with the atoms to which they are bonded form cycloalkyl or heterocycloalkyl; R15 and R16 independently are alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl or together with the atom to which they are bonded form a heterocycloalkyl group; R17, R18 and R19 independently are H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl or acyl; R20 is H, OH, or any suitable organic moiety; R21, R22, R23 and R24 are independently H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, acyl, or thioacyl or any two of R21, R22, R23 and R24 together with the atom(s) to which they are bonded form heterocycloalkyl and R25 and R26 are independently H, alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. The compound of formula (I) has antipicornaviral activity with an EC50 less than or equal to 10 mM in the HI-HeLa cell culture assay. A pharmaceutical composition thereof is useful for treating a disease condition mediated by picornaviral protease activity or for inhibiting the activity of a picornaviral 36 protease or rhinoviral protease.
机译:化合物,其药学上可接受的前药,盐,活性代谢物或溶剂化物具有式(I),其中:M为O或S; R1是H,F,烷基,OH,SH或O-烷基; R2和R5独立地为H,式2a或式2b的基团或烷基,条件是该烷基与式2a或2b不同,进一步的条件是R2或R5中的至少一个必须为式2a或2b的基团; R3和R6独立地是H,F,烷基,环烷基,杂环烷基,芳基,杂芳基,-C(O)R17,-OR17,-SR17,-NR17R18,-NR19NR17R18或-NR17OR18或R3和R6以及碳原子一起为它们连接成环烷基或杂环烷基; R7是H,烷基,环烷基,杂环烷基,芳基,杂芳基,-OR17,-SR17,-NR17R18,-NR19NR17R18或-NR17OR18或R7与R3或R6一起,并且它们所连接的原子形成杂环烷基; Z和Z1独立地为H,F,烷基,环烷基,杂环烷基,芳基,杂芳基,-C(O)R21,-CO2R21,-CN,-C(O)NR21R22,-C(O)NR21OR22,-C(S )R21,-C(S)NR21R22,-NO2,-SOR21,-SO2R21,-SO2NR21R22,-SO(NR21)(OR22),-SONR21,-SO3R21,-PO(OR21)2,-PO(R21)( R22),-PO(NR21R22)(OR23),-PO(NR21R22)(NR23R24),-C(O)NR21NR22R23或-C(S)NR21NR22R23或Z1与R1以及与Z1和R1结合的原子环烷基或杂环烷基或Z和Z1与它们所键合的原子一起形成环烷基或杂环烷基;在式2a中:a)X为-CR2-,-CF2-,-CHF-或-S-,Y1为-O-,-S-,-NR12-​​,-C(R13)(R14)-,-C (O)-,-C(S)-或-C(CR13R14)-; b)X为= CH或= CF且Y1为= CH或= CF或c)X和Y1与Q'形成三元环,其中Q'为-C(R10)(R11)-或-O -,X为-CH-或-CF-,且Y 1为-CH-,-CF-或-C(烷基)-; A1为C,CH,CF,S,P,Se,N,NR15,S(O),Se(O),P-OR15或P-NR15R16; D1是具有能够形成氢键的孤对电子的部分; B1是H,F,烷基,环烷基,杂环烷基,芳基,杂芳基,-OR17,-SR17,-NR17R18,-NR19NR17R18或-NR17OR18或一起D1-A1-B1任选地形成硝基,其中i是i)当D1是带有可形成氢键的孤对电子的ºN部分时,B1不存在; ii)当A1是sp3碳时,当D1是具有能形成氢键的孤对电子的-NR25R26部分时,B1不是-NR17R18;在式2b中:d)X是-CR 2-,-CF 2-,-CHF-或-S-,且Y 2是-O-,-S-,-NR'12-,-C(R'13)(R' 14)-,-C(O)-,-C(S)-或-C(CR'13R'14)-; e)X是= CH或= CF且Y2是= CH或= CF或f)X和Y2与Q'一起形成三元环,其中Q'是-C(R10)(R11)-或-O- X为-CH-或-CF-,Y 2为-CH-,-CF-或-C(烷基); A 2为C,CH,CF,S,P,Se,N,NR15,S(O),Se(O),P-OR15或P-NR15R16; D2是具有能够形成氢键的孤对电子的部分,并且B2是H,F,烷基,环烷基,杂环烷基,芳基,杂芳基,-OR17,-SR17,-NR17R18,-NR19NR17R18或-NR17OR18或任何组合Y2,A2,B2和D2中的一个任选地可以形成环烷基,杂环烷基,芳基或杂芳基,条件是当D2为具有可形成氢键的孤对电子的N部分时,B2不存在; R10和R11独立地为H,卤素或烷基,或与它们所连接的碳原子一起形成环烷基或杂环烷基; R12为H或烷基; R'12是H,烷基,环烷基,杂环烷基,芳基,杂芳基,-OR'13,-NR'13R'14,C(O)R'13,-SO2-R'13或-C(S)R' 13; R 13和R 14独立地为H,F或烷基,或与它们键合的原子一起形成环烷基或杂环烷基; R'13和R'14独立地为H,F或烷基,环烷基,杂环烷基,芳基,杂芳基或与它们所键合的原子一起形成环烷基或杂环烷基; R15和R16独立地是烷基,环烷基,杂环烷基,芳基或杂芳基或与它们键合的原子一起形成杂环烷基; R17,R18和R19独立地为H,烷基,环烷基,杂环烷基,芳基,杂芳基或酰基; R 20为H,OH或任何合适的有机部分; R 21,R 22,R 23和R 24独立地为H,烷基,环烷基,杂环烷基,芳基,杂芳基,酰基或硫代酰基或R 21,R 22,R 23和R 24中的任何两个与它们所键合的原子一起形成杂环烷基R 25和R 26独立地为H,烷基,环烷基,杂环烷基,芳基或杂芳基。式(I)的化合物在HI-HeLa细胞培养测定法中具有抗picornaviral病毒活性,EC 50小于或等于10mM。其药物组合物可用于治疗由微核病毒载体活性介导的疾病或抑制微核病毒36蛋白酶或鼻病毒蛋白酶的活性。

著录项

  • 公开/公告号NZ501315A

    专利类型

  • 公开/公告日2001-08-31

    原文格式PDF

  • 申请/专利权人 AGOURON PHARMACEUTICALS INC;

    申请/专利号NZ19980501315

  • 发明设计人 DRAGOVICH PETER S;ZHOU RU;PRINS THOMAS J;

    申请日1998-03-26

  • 分类号C07C271/22;C07C333/04;C07D213/30;C07D339/06;C07D339/08;C07D261/18;A61K31/325;A61K31/44;C07C271/34;

  • 国家 NZ

  • 入库时间 2022-08-22 01:24:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号